Understanding how brain mechanisms affect rapid antidepressant responses
Cortical GABAergic mechanisms underlying rapid and sustained antidepressant responses
This study is looking at how certain brain chemicals might help antidepressants like ketamine work faster and better for people with major depressive disorder, with the goal of finding new ways to improve treatment for those who struggle with depression.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11042712 on NIH RePORTER |
What this research studies
This research investigates the brain's GABAergic mechanisms that may influence how quickly and effectively antidepressants, particularly ketamine, work in treating major depressive disorder (MDD). It aims to explore the interactions between excitatory and inhibitory neurons in the brain, focusing on how these interactions can lead to rapid and sustained improvements in mood. By studying these mechanisms, the research hopes to uncover new insights that could enhance the effectiveness of current antidepressant treatments and address the limitations faced by many patients. The approach includes both animal models and potential implications for human treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with major depressive disorder, particularly those who have not responded well to traditional antidepressant therapies.
Not a fit: Patients with mild depressive symptoms or those who do not have a diagnosis of major depressive disorder may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to faster and more effective treatments for patients suffering from major depressive disorder.
How similar studies have performed: Previous studies have shown promising results with ketamine and its effects on GABAergic mechanisms, indicating that this research builds on established findings in the field.
Where this research is happening
Rochester, United States
- University of Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Fogaca, Manoela — University of Rochester
- Study coordinator: Fogaca, Manoela
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.